GlobeNewswire·Nov 11, 2026, 4:05 PM ET

Vivani Medical Reports Third Quarter 2026 Financial Results and Provides Business Update

VANI

Vivani Medical reported third-quarter 2026 financial results on November 11, 2026, with a net loss of $7.3 million compared to $6.5 million in the same period of 2025.
Top-line results for the SLIM-1™ Phase 1 trial of the NPM-139 semaglutide implant are anticipated to be announced later this week.
The company announced a merger between its subsidiary Cortigent Inc. and ClearOne Inc., which is awaiting final regulatory approvals to establish Cortigent as a standalone Nasdaq-traded company under the ticker CRGT.
Vivani holds $15.5 million in cash, cash equivalents, and restricted cash as of September 30, 2026, down from $20.8 million in June 2026.
Research and development expenses increased by 11% to $5.0 million in the third quarter, primarily due to higher clinical trial costs in the Biopharm Division.
General and administrative expenses rose by 14% to $2.5 million, driven by increased personnel costs in both the Neurostimulation and Biopharm Divisions.
The SLIM-1 trial enrolled 20 GLP-1 naïve participants in Australia to evaluate the safety, tolerability, pharmacokinetics, and weight changes of the NPM-139 implant versus Wegovy®.
Vivani signed an agreement with Novo Nordisk in July 2026 to evaluate NPM-139 for chronic weight management, with no exclusivity provisions attached.
Upcoming milestones include the release of SLIM-1 data in November 2026, an IND application submission for a Phase 2 study planned for 2027, and the transition of Cortigent to an independent public company.
The company's proprietary NanoPortal™ technology aims to deliver ultra-long-acting drug implants for once- or twice-yearly administration to improve medication adherence.

Company: Vivani Medical, Inc.
Keywords: Nasdaq:VANI, Vivani Medical, Inc., Adam Mendelsohn, GLP-1, obesity, semaglutide, VANI, Vivani